Canadian Blood Services

Canadian Blood Services is an independent Canadian charitable organization that operates a national blood and biological-products system for the provincial and territorial governments, with Quebec served by the separate Héma-Québec system. It was created in 1998 after the federal, provincial and territorial governments agreed to establish a successor to the Canadian Red Cross blood system. The organization is not a department of the federal government and is funded primarily by Canada's provinces and territories. Its central role is to recruit donors, collect blood and plasma, test donations, manufacture blood components and distribute products to hospitals and other health-care providers. Its services include whole-blood collection, platelet and plasma collection, donor screening, infectious-disease testing, inventory management and the supply of components such as red blood cells, platelets and plasma. It also oversees or supports the production and procurement of plasma-derived medicines, including immune globulin, and monitors the national availability of plasma needed for these therapies. Canadian Blood Services also operates national programs beyond routine transfusion medicine. These include the OneMatch stem-cell and marrow donor program, stem-cell donor matching and collection, and national organ and tissue coordination activities. Provincial and territorial systems can access national transplant infrastructure for interprovincial sharing and related programs. The organization works with Héma-Québec to exchange information, coordinate during shortages and strengthen the resilience of Canada's blood and transplant systems. Safety is built around several layers of donor eligibility assessment and post-collection testing. Donors are asked about current health, medication, vaccination, travel, medical history and behaviours that could affect recipient safety. Donations are screened for infectious diseases including HIV and hepatitis, while the system also investigates suspected transfusion-transmitted infections and tracks emerging threats. These controls are intended to balance the need for a dependable supply with the lowest practical risk to recipients. A prominent area of policy development has been donor eligibility for men who have sex with men and for transgender donors. The organization moved from a long-standing MSM-related deferral to shorter time-based rules and, in September 2022, introduced questions based on recent sexual behaviours rather than gender or sexual orientation. The revised questionnaire focuses on new or multiple sexual partners and anal sex during the preceding three months. Canadian Blood Services has described the change as an evidence-based effort to make screening more inclusive without removing safeguards against recently acquired infections. The policy history also generated sustained criticism from LGBTQ+ advocates, who argued that individual risk behaviour was more appropriate than identity-linked restrictions. Plasma sufficiency remains a strategic challenge. Canadian Blood Services collects plasma from unpaid donors, but domestic collection has historically supplied only a minority of the country's immune-globulin requirement, leaving Canada dependent on purchased finished products and plasma-derived medicines made from paid-donor plasma, particularly from the United States. Expanding domestic plasma collection, donor participation and collection capacity has therefore become an important operational priority. Overall, Canadian Blood Services functions less like a conventional consumer brand than a publicly funded health-care service and national biological-supply operator whose reputation depends on safety, reliability, donor trust and equitable access.

Canadian Blood Services emerged from the restructuring of Canada's blood system after the tainted-blood crisis of the 1980s. The Canadian Red Cross Blood Transfusion Service had previously played the central national role, but the crisis exposed serious weaknesses in governance, quality control and accountability. The Krever Commission's investigation and the resulting reforms contributed to the decision to establish a new blood authority at arm's length from government and with a clearer national mandate. In 1998, the federal, provincial and territorial governments created Canadian Blood Services through a memorandum of understanding. Quebec did not join the organization’s core operating structure because it maintained its own provincial blood operator, Héma-Québec. Canadian Blood Services consequently became responsible for blood services across the other provinces and territories, while maintaining a cooperative relationship with Héma-Québec for interprovincial coordination, information exchange, emergency support and selected national programs. The organization developed an integrated chain covering donor recruitment, collection, laboratory testing, component processing, inventory management and delivery to hospitals. Its routine collection model has relied substantially on voluntary, unpaid donors. Whole blood has remained the principal collection activity, supplemented by apheresis collection of plasma and platelets. Donations are screened through donor interviews and laboratory testing for infectious risks, while surveillance and investigation programs are used to identify possible transfusion-transmitted infections and emerging threats. Its mandate broadened beyond conventional blood banking. Canadian Blood Services became involved in national stem-cell donor registration and matching through the OneMatch network and supports the collection and allocation of stem-cell products. It also participates in national organ and tissue coordination and interprovincial sharing programs. These activities reflect the organization's role as part of Canada's broader publicly funded health-care infrastructure rather than as a conventional commercial blood-products company. Donor eligibility policy has been a recurring subject of legal, scientific and social debate. The predecessor blood service introduced restrictions on men who had sex with men during the HIV/AIDS crisis of the 1980s. Canadian Blood Services reviewed the issue beginning in 2006, but its board decided in 2007 to retain the restriction while gathering more evidence. A 2010 Ontario Superior Court decision upheld the then-existing criteria against a Charter challenge, accepting the stated connection to blood-safety considerations. Policy subsequently changed in stages. In 2011, the board approved replacing the permanent-style restriction with a defined deferral. The five-year rule took effect in 2013, was reduced to one year in 2016 and then to three months in 2019. In September 2022, the organization moved to a behaviour-based approach applied to all donors. The revised screening asks about recent new or multiple sexual partners and anal sex, rather than directly excluding donors according to sexual orientation. The change followed research, community consultation and regulatory review, while critics continued to debate whether the remaining criteria were sufficiently individualized. Transgender donor policy also evolved. Criteria introduced in 2016 addressed donors according to surgical history and relevant screening rules, including a post-surgical deferral period and measures intended to reduce transfusion-related acute lung injury risks associated with plasma from donors who may have pregnancy-related antibodies. The organization held consultations with transgender and gender-non-binary communities as it refined these policies. Plasma supply has become one of the system's most important strategic issues. Domestic volunteer plasma collection has not historically met Canada's full requirement for immune globulin and other plasma-derived medicines. As a result, Canada has purchased finished products manufactured from plasma collected in other countries, especially the United States. Canadian Blood Services has treated increased domestic plasma collection, new collection capacity and donor recruitment as priorities while continuing to operate within Canada's not-for-profit framework. Its current identity is therefore defined by two connected responsibilities: maintaining a safe, reliable national supply of blood components and strengthening long-term Canadian capacity for plasma, stem-cell and transplant-related services.

• 2022

  Sexual-behaviour-based screening launches

  [3]Blood donor eligibilityblood.ca

  Canadian Blood Services introduces a questionnaire applied regardless of gender or sexual orientation, focusing on recent partner and sexual behaviours.

• 2019

  MSM deferral is reduced to three months

  [1]Canadian Blood Servicesen.wikipedia.org

  Health Canada approves a further reduction in the waiting period for MSM donors.

• 2016

  One-year MSM deferral and transgender criteria take effect

  [1]Canadian Blood Servicesen.wikipedia.org

  The MSM waiting period is reduced to one year, and revised eligibility criteria for transgender donors are implemented.

• 2013

  Five-year MSM deferral takes effect

  [1]Canadian Blood Servicesen.wikipedia.org

  The previous restriction covering sexual activity since 1977 is replaced by a five-year deferral from the last sexual contact.

• 2011

  Board approves a time-limited MSM deferral

  [1]Canadian Blood Servicesen.wikipedia.org

  The board approves replacing the permanent-style restriction with a defined deferral period.

• 2007

  Board retains the existing MSM restriction

  [1]Canadian Blood Servicesen.wikipedia.org

  After its review, the board maintains the restriction and supports further evidence gathering.

• 2006

  Review of MSM donor restrictions begins

  [1]Canadian Blood Servicesen.wikipedia.org

  Canadian Blood Services begins a formal examination of its restrictions on men who have sex with men.

• 1998

  Canadian Blood Services is established

  [1]Canadian Blood Servicesen.wikipedia.org

  Federal, provincial and territorial governments create the organization through a memorandum of understanding as Canada's blood authority outside Quebec.

A trusted, evidence-led national health-care service that protects the blood supply, supports hospitals and patients, and connects Canadian donors with transfusion, plasma, stem-cell and transplant needs.

• Blood components

  Whole blood and red blood cells

  Canadian Blood Services collects whole blood, separates it into clinical components and supplies red blood cell products to hospitals for patients who need oxygen-carrying blood replacement. Whole-blood donation is the organization's principal collection activity and supports routine care, surgery, trauma treatment and other hospital services.

• Blood components

  Platelets

  Platelets are collected through whole-blood processing and plateletpheresis. They are distributed for clinical situations in which patients require help controlling or preventing bleeding, including some cancer treatments, surgeries and serious injuries.

• Blood components and source material

  Plasma

  The organization collects plasma from volunteer donors through whole-blood processing and plasmapheresis. Plasma may be transfused directly or sent for fractionation into medicines containing proteins used in the treatment of immune deficiencies, bleeding disorders, burns and other conditions.

• Stem-cell services

  OneMatch Stem Cell and Marrow Network

  OneMatch connects potential stem-cell and marrow donors with patients who require a transplant. The program maintains donor information, supports matching and coordinates collection and transplantation activities with Canadian and international partners.

• Transplant services

  Organ and tissue coordination

  Canadian Blood Services supports national transplant infrastructure and interprovincial organ-sharing programs. These services help jurisdictions coordinate access to organs and related transplant resources when suitable matches are not available locally.

• Criticism of commercial incentives and paid-plasma collection

  Canadian Blood Services has faced criticism from commentators who argue that movement toward commercial plasma collection or monetary incentives could weaken Canada's traditional voluntary, unpaid-donor model. The issue reflects a broader debate about supply security, donor ethics and reliance on plasma collected from paid donors in the United States.

  Source

Read more

• Blood donor recruitment and collection

  Canada outside Quebec

  The organization conducts ongoing donor-recruitment and collection activity to maintain hospital inventories of blood components and encourage regular voluntary, unpaid donation.

  Outcome. Ongoing operational program; no single campaign outcome is specified in the reference material.

  Source
• Plasma donor recruitment

  Canada outside Quebec

  Canadian Blood Services has promoted increased plasma donation and collection capacity to reduce dependence on imported plasma-derived medicines and improve national resilience.

  Outcome. Domestic plasma collection remains a continuing strategic priority.

  Source

• 2022

  Adopt gender- and orientation-neutral sexual-risk screeningStrategy

  Background

  Research, regulatory review and consultations supported moving away from a donor rule explicitly tied to MSM status.

  Action taken

  On September 11, 2022, the organization began asking all donors about new or multiple sexual partners and anal sex during the preceding three months. A qualifying risk profile can trigger a three-month deferral.

  Aftermath

  The change removed the MSM-specific wording while retaining behaviour-based safeguards intended to address recently acquired HIV risk.

  Source

• 2019

  Reduce the MSM deferral to three monthsOther

  Background

  The organization sought to align eligibility more closely with the detection window of current testing while retaining a precautionary interval.

  Action taken

  The waiting period for MSM donors was reduced from one year to three months.

  Aftermath

  The rule remained controversial and was ultimately replaced by sexual-behaviour-based screening.

  Source

• 2016

  Reduce the MSM deferral to one yearOther

  Background

  Canadian Blood Services requested a further evidence-based reduction in the waiting period and received Health Canada approval.

  Action taken

  The one-year deferral took effect on August 15, 2016.

  Aftermath

  The organization continued research and consultation on more inclusive donor-screening methods.

  Source

• 2013

  Replace the lifetime-style MSM restriction with a five-year deferralOther

  Background

  The organization and Health Canada considered the HIV risk associated with the existing policy and the need to preserve blood safety while reducing the breadth of the restriction.

  Action taken

  The deferral was changed to five years from the last sexual contact between men and took effect in July 2013.

  Aftermath

  The policy was later shortened to one year, then three months, before being replaced by behaviour-based screening in 2022.

  Source

• Prioritize expansion of domestic plasma collectionStrategy

  Background

  Canadian collection has historically supplied only part of the country's immune-globulin requirement, creating dependence on imported finished products and foreign plasma supply.

  Action taken

  Canadian Blood Services has treated donor recruitment, plasma collection capacity and greater domestic supply as strategic priorities.

  Aftermath

  The organization continues to balance voluntary donation principles with the need for a secure and sufficient supply of plasma-derived medicines.

  Source

1. 1Canadian Blood Servicesen.wikipedia.org
2. 2Canadian Blood Services official websiteblood.ca
3. 3Blood donor eligibilityblood.ca
4. 4Plasma donation and supplyblood.ca